DUPIXENT (dupilumab), developed by Sanofi and Regeneron, has added another significant achievement to its portfolio by receiving the first-ever biologic approval for treating Chronic Obstructive Pulmonary Disease (COPD).
DUPIXENT Expands Its Legacy with First Biologic Approval for COPD: Click Here To Know More: https://www.delveinsight.com/b....log/dupixent-for-cop
Like
Comment
Share
